UCLA Health Activation & Continuous Innovation Study Update
Filed with ASX · · 5 pages · English
Summary by 6ix AI
EMvision Medical Devices Ltd. provides an update on the UCLA Health activation and Continuous Innovation Study for its emu™ brain scanner device. The UCLA Health site is set to activate soon, completing the initiation of all trial sites for the pivotal study. The company is on track for its De Novo submission, with recruitment targets expected to be met in the first half of the upcoming year. Additionally, Box Hill Hospital has been added as a new site for the Continuous Innovation Study.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Story so far
Earlier from EMvision Medical Devices
- EMVision Awarded $3m Grant For Regional Benefits Study
- First Responder Program Advanced & Grant Milestone Achieved
- Key Developments in Pivotal Trial & Innovation Study
- EMVision Awarded $5m Non-Dilutive Government Grant
- Additional Pivotal Trial Site Activations
Later from EMvision Medical Devices
- Appendix 4E & Annual Report to 30 June 2025
- Trading Halt
- Firm Commitments for $12.0M Placement & Launch of SPP
- Pre-Hospital MSU Study Commences with First Responder Device
- SPP Offer Document & Option Prospectus
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices